Heinrich Kovar

Dr. Heinrich Kovar

orcid

Research Focus & Metrics

Academic Career Length

42Years (1985-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 1992 in Nature
Verified
Journal Article
Closed access
PDF file
ODOlivier Delattre
Olivier Delattre
JZJessica Zucman
Jessica Zucman
BPBéatrice Plougastel
Béatrice Plougastel
CDChantal Desmaze
Chantal Desmaze
TMThomas Melot
Thomas Melot
GTGilles Thomas
Gilles Thomas

20 September 2015 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
NGNathalie Gaspar
Nathalie Gaspar
DHDouglas S. Hawkins
Douglas S. Hawkins
UDUta Dirksen
Uta Dirksen
ILIan J. Lewis
Ian J. Lewis
SFStefano Ferrari
Stefano Ferrari
OOOdile Oberlin
Odile Oberlin
Ewing sarcoma (ES) is an aggressive sarcoma of bone and soft tissue occurring at any age with a peak incidence in adolescents and young adults. The treatment of ES relies on a multidisciplinary approach, coupling risk-adapted intensive neoadjuvant and adjuvant chemotherapies with surgery and/or radiotherapy for control of the primary site and possible metastatic disease. The optimization of ES multimodality therapeutic strategies has resulted from the efforts of several national and international groups in Europe and North America and from cooperation between pediatric and medical oncologists. Successive first-line trials addressed the efficacy of various cyclic combinations of drugs incorporating doxorubicin, vincristine, cyclophosphamide, ifosfamide, etoposide, and dactinomycin and identified prognostic factors now used to tailor therapies. The role of high-dose chemotherapy is still debated. Current 5-year overall survival for patients with localized disease is 65% to 75%. Patients with metastases have a 5-year overall survival < 30%, except for those with isolated pulmonary metastasis (approximately 50%). Patients with recurrence have a dismal prognosis. The many insights into the biology of the EWS-FLI1 protein in the initiation and progression of ES remain to be translated into novel therapeutic strategies. Current options and future approaches will be discussed.

1 April 1991 in Cancer
Verified
Journal Article
Closed access
PDF file
IAInge M. Ambros
Inge M. Ambros
PAPeter Ambros
Peter Ambros
SSSabine Strehl
Sabine Strehl
HKHeinrich Kovar
Heinrich Kovar
HGHelmut Gadner
Helmut Gadner
MSMechthild Salzer-Kuntschik
Mechthild Salzer-Kuntschik

1 May 2006 in The Oncologist
Verified
Journal Article
Closed access
PDF file
MBMark Bernstein
Mark Bernstein
HKHeinrich Kovar
Heinrich Kovar
MPMichael Paulussen
Michael Paulussen
RRR. Lor Randall
R. Lor Randall
ASAndreas Schuck
Andreas Schuck
HJHerbert Juergensg
Herbert Juergensg
Ewing’s sarcoma is the second most frequent primary bone cancer, with approximately 225 new cases diagnosed each year in patients less than 20 years of age in North America. It is one of the pediatric small round blue cell tumors, characterized by strong membrane expression of CD99 in a chain-mail pattern and negativity for lymphoid (CD45), rhabdomyosarcoma (myogenin, desmin, actin) and neuroblastoma (neurofilament protein) markers. Pathognomonic translocations involving the ews gene on chromosome 22 and an ets-type gene, most commonly the fli1 gene on chromosome 11, are implicated in the great majority of cases. Clinical presentation is usually dominated by local bone pain and a mass. Imaging reveals a technetium pyrophosphate avid lesion that, on plain radiograph, is destructive, diaphyseal and classically causes layered periosteal calcification. Magnetic resonance best defines the extent of the lesion. Biopsy should be undertaken by an experienced orthopedic oncologist. Approximately three quarters of patients have initially localized disease. About two thirds survive disease-free. Management, preferably at a specialist center with a multi-disciplinary team, includes both local control—either surgery, radiation or a combination—and systemic chemotherapy. Chemotherapy includes cyclic combinations, incorporating vincristine, doxorubicin, cyclophosphamide, etoposide, ifosfamide and occasionally actinomycin D. Topotecan in combination with cyclophosphamide has shown preliminary activity. Patients with initially metastatic disease fare less well, with about one quarter surviving. Studies incorporating intensive therapy followed by stem cell infusion show no clear benefit. New approaches include anti-angiogenic therapy, particularly since vascular endothelial growth factor is an apparent downstream target of the ews-fli1 oncogene.

14 April 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
SZStefan K. Zöllner
Stefan K. Zöllner
JAJames F. Amatruda
James F. Amatruda
SBSebastian Bauer
Sebastian Bauer
SCStéphane Collaud
Stéphane Collaud
ENRIQUE DE ALAVAENRIQUE DE ALAVA
ENRIQUE DE ALAVA
Uta DirksenUta Dirksen
Uta Dirksen
Ewing sarcoma, a highly aggressive bone and soft-tissue cancer, is considered a prime example of the paradigms of a translocation-positive sarcoma: a genetically rather simple disease with a specific and neomorphic-potential therapeutic target, whose oncogenic role was irrefutably defined decades ago. This is a disease that by definition has micrometastatic disease at diagnosis and a dismal prognosis for patients with macrometastatic or recurrent disease. International collaborations have defined the current standard of care in prospective studies, delivering multiple cycles of systemic therapy combined with local treatment; both are associated with significant morbidity that may result in strong psychological and physical burden for survivors. Nevertheless, the combination of non-directed chemotherapeutics and ever-evolving local modalities nowadays achieve a realistic chance of cure for the majority of patients with Ewing sarcoma. In this review, we focus on the current standard of diagnosis and treatment while attempting to answer some of the most pressing questions in clinical practice. In addition, this review provides scientific answers to clinical phenomena and occasionally defines the resulting translational studies needed to overcome the hurdle of treatment-associated morbidities and, most importantly, non-survival.

31 March 2009 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
Günther HS RichterGünther HS Richter
Günther HS Richter
SPStephanie Plehm
Stephanie Plehm
AFAnnette Fasan
Annette Fasan
SRSabine Rössler
Sabine Rössler
RURebekka Unland
Rebekka Unland
SBStefan Burdach
Stefan Burdach
Ewing tumors (ET) are highly malignant, localized in bone or soft tissue, and are molecularly defined by ews/ets translocations. DNA microarray analysis revealed a relationship of ET to both endothelium and fetal neural crest. We identified expression of histone methyltransferase enhancer of Zeste,Drosophila, Homolog 2 (EZH2) to be increased in ET. Suppressive activity of EZH2 maintains stemness in normal and malignant cells. Here, we found EWS/FLI1 bound to the EZH2 promoter in vivo, and induced EZH2 expression in ET and mesenchymal stem cells. Down-regulation of EZH2 by RNA interference in ET suppressed oncogenic transformation by inhibiting clonogenicity in vitro. Similarly, tumor development and metastasis was suppressed in immunodeficient Rag2−/−γC−/−mice. EZH2-mediated gene silencing was shown to be dependent on histone deacetylase (HDAC) activity. Subsequent microarray analysis of EZH2 knock down, HDAC-inhibitor treatment and confirmation in independent assays revealed an undifferentiated phenotype maintained by EZH2 in ET. EZH2 regulated stemness genes such as nerve growth factor receptor (NGFR), as well as genes involved in neuroectodermal and endothelial differentiation (EMP1, EPHB2, GFAP, and GAP43). These data suggest that EZH2 might have a central role in ET pathology by shaping the oncogenicity and stem cell phenotype of this tumor.